-
The White House unveiled a list of 48 drugs whose prices increased faster than the rate of inflation this year. Under a new law, drugmakers must pay rebates to the government because of it.
-
Colorado officials say they haven’t been able to stand up a program to import drugs from Canada because of drugmaker opposition — and the Biden administration’s inaction.
-
The governors square off in a first-of-its-kind debate Thursday. Let's compare the political rivals’ health care positions, showing how their policies helped — or hinder— the health of their states’ residents.
-
A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, but some pharmacists say it’s enabling these price brokers to simply do new things unfairly.
-
The CDC’s RSV vaccination recommendations beg the question: How much should an immunization that will possibly be given to millions of Americans cost to be truly valuable?
-
Joe Biden's pick for the post next goes to a floor vote, but not before committee Chair Bernie Sanders tried to tie it to reducing the cost of prescription drugs.
-
The FDA had been expected to decide by next week, but a back-and-forth between state and federal officials about details of the proposal means the wait will continue, a court document says.
-
Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.
-
Before COVID, hepatitis C held the distinction of claiming more American lives each year than any other infectious disease — that’s despite the marketing of several relatively affordable, highly effective treatments.
-
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices have not delivered on those savings.